Greenwich LifeSciences market cap GLSI
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Nov 2, 2026
- $241.6M
- Highest close in our data
- $688.6M
- Apr 2021
Greenwich LifeSciences is worth $241.6M at the close on Nov 2, 2026, at $16.46 a share.
That is up 105% over the last year and down 50% over five years.
Its highest close in our data was $688.6M in Apr 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $241.6M | $190.5M | $416.6M | −16% |
| 2025 | $286.7M | $112.9M | $286.7M | +90% |
| 2024 | $151.2M | $108.6M | $256.2M | +12% |
| 2023 | $135.2M | $106.4M | $262.5M | −31% |
| 2022 | $195.3M | $95.6M | $304.1M | −39% |
| 2021 | $319.3M | $276.4M | $688.6M | −27% |
| 2020 | $438.3M | $63.9M | $673.1M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Greenwich LifeSciences' size, closest first, today.
| Company | Market cap |
|---|---|
| GLSIGreenwich LifeSciences | $241.6M |
| NATRNatures Sunshine Products | $211.5M |
| CRMDCorMedix | $420.1M |
| ARVNArvinas | $491.7M |
| PBYIPuma Biotechnology | $525.5M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $599.8M |
| COLLCollegium Pharmaceutical | $770.9M |
| ABUSArbutus Biopharma | $791.4M |
| LFVNLifevantage | $73.5M |
| SPROSpero Therapeutics | $60.6M |
| Peer median | $508.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Greenwich LifeSciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.